Silencing of  WNK2 is associated with upregulation of MMP2 and JNK in gliomas by Costa, Angela Margarida et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2014
Silencing of WNK2 is associated with upregulation of MMP2 and 
JNK in gliomas
Angela Margarida Costa1,2, Filipe Pinto1,2, Olga Martinho1,2, Maria José Oliveira3, 
Peter Jordan4,5, Rui Manuel Reis1,2,6
1 ICVS-Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, Campus Gualtar, Braga 
4710-057, Portugal
2ICVS/3B’s - PT -Government Associate Laboratory, Braga/Guimarães 4710-057, Portugal
3INEB-Institute of Biomedical Engineering, Porto 4150-180, Portugal
4Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Lisbon 1649-016, Portugal
5BioFig-Center of Biodiversity, Functional and Integrative Genomics, Lisbon 1649-016, Portugal
6Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil
Correspondence to:
Rui Manuel Reis, e-mail: rreis@ecsaude.uminho.pt
Keywords: WNK2, MMP2, JNK, gliomas, invasion
Received: July 16, 2014 Accepted: November 25, 2014 Published: December 22, 2014
ABSTRACT
Matrix metalloproteinases (MMPs) are proteolytic enzymes that degrade 
extracellular matrix (ECM), thus assisting invasion. Upregulation of MMPs, frequently 
reported in gliomas, is associated with aggressive behavior. WNK2 is a tumor 
suppressor gene expressed in normal brain, and silenced by promoter methylation 
in gliomas. Patients without WNK2 exhibited poor prognosis, and its downregulation 
was associated with increased glioma cell invasion.
Here we showed that MMP2 expression and activity are increased in glioma 
cell lines that do not express WNK2. Also, WNK2 inhibited JNK, a process associated 
with decreasing levels of MMP2. Thus, WNK2 promoter methylation and silencing in 
gliomas is associated with increased JNK activation and MMP2 expression and activity, 
thus explaining in part tumor cell invasion potential.
INTRODUCTION
Gliomas are the most common primary brain tumors, 
and among them, glioblastomas are not only the most 
frequent, accounting for approximately 50% of all gliomas, 
but are also the most aggressive subtype, with a mean 
survival of 16 months [1]. Due to their high infiltrative 
and invasive capacity into adjacent tissues, these tumors 
are extremely difficult to be completely resected during 
surgery, leading to tumor recurrence, and ultimately patient 
death [2]. Preventing cancer cell invasion could increase 
survival of gliomas patients, but the mechanisms that 
govern this process are poorly understood.
To invade, cancer cells must undergo several 
changes in cell-cell and cell-matrix adhesion, in migration 
and proteolysis capacities, and ectopic survival [3]. 
During cancer cell invasion into adjacent healthy brain 
tissue, cells need to overcome the extracellular matrix 
barrier, through a process that involves a tightly regulated 
proteolytic mechanism, in which MMPs play a pivotal 
role [3]. MMPs are able to degrade all components of the 
extracellular matrix, eliminating the physical barrier to cell 
movement, and creating the route to the invading cells [4].
MMPs are a family of zinc-dependent enzymes, 
which in the majority of cases are generated and secreted 
as an inactive form, a pro-enzyme, that has to be 
processed to become active, autocatalytically or by other 
proteinases [4, 5]. MMPs are tightly regulated at several 
levels: transcription, compartmentalization, pro-enzyme 
activation, and by the action of specific inhibitors, such 
as tissue inhibitors of MMPs (TIMPs) [6]. Although their 
main function is extracellular matrix degradation, they 
are also responsible for the modification of cell surface 
receptors, release of growth factors, and regulation of 
inflammation and immunity cytokines, cell-cell adhesion 
molecules, and other proteinases [6–8]. In gliomas, 
the importance of MMPs for tumor invasion into the 
surrounding tissues is well documented [9, 10]. However, 
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the molecular mechanisms that modulate MMPs secretion 
and activation remain to be clarified.
WNK2, a serine/threonine kinase, is a member 
of the WNK (with no lysine (K)) protein kinase 
subfamily, predominantly expressed in brain, heart 
muscle, small intestine, and colon [11–13]. In epithelial 
cells the silencing of WNK2 was reported to increase 
GTP-loading of Rac1, and the consequent Rac1 
activation resulted in increased proliferation mediated 
by MEK and ERK activation [13, 14]. In tumors, WNK2 
expression was found downregulated by promoter 
hypermethylation both in human gliomas [15, 16] as 
in other tumor types [17–19]. Given the importance 
of WNK2 in cancer context, it is important to identify 
its upstream and downstream targets and determine 
how they influence WNK2 function. In gliomas, our 
group recently reported that WNK2 downregulation 
results in increased cell proliferation, tumor growth, 
cell migration and invasion [16], corroborating other’s 
theory that WNK2 functions as a tumor-suppressor gene 
[15, 19].
In the present study, we report for the first 
time that WNK2 is a modulator of MMPs, negatively 
regulating MMP2 expression and activity, through 
a mechanism involving inactivation of JNK. We further 
demonstrate that downregulation of MMP2 by WNK2 
is associated with decreased levels of glioma cell 
invasion.
RESULTS
WNK2 protein expression associates with 
reduced MMP2 expression and activity
A high percentage of WNK2 promoter methylation 
in gliomas was reported by our and other groups 
[15, 16], and consequent decrease in the enzyme 
protein expression was associated with increased levels 
of glioma cell invasion [16]. We have also previously 
showed that WNK2 downregulation induces Rac1 
activation, leading to increased migration, an important 
cellular alteration involved in the invasion process 
[16]. However, the role of WNK2 downregulation in 
proteolytic events related to glioma cell invasion was 
not explored. Due to the pivotal role of MMPs in ECM 
degradation, and consequently to the invasion process, 
together with the documented association between 
MMP2 and MMP9 expression and severity of disease 
in gliomas [20, 21], we interrogated whether the 
WNK2 methylation status was associated with MMP2 
and MMP9 activity levels in a panel of eight glioma 
cell lines. For that, the pattern of WNK2 promoter 
methylation was analyzed by methylation specific PCR 
(Figure 1A). Additionally, the levels of MMP2 and 
MMP9 activity were analyzed by gelatin zymography, 
using conditioned media of these cells, cultured for 
24 hours in serum-free medium. As demonstrated, 
WNK2 promoter methylation is associated with 
increased MMP2 activation levels, and in general also 
with increased MMP9 protein levels (Figure 1B). Then, 
two models were chosen to test whether the MMP2 and 
MMP9 levels were also altered at transcript level: the 
A172 cell line, with WNK2 promoter methylation and 
consequent lack of WNK2 expression, and the SW1088 
cell line, with no WNK2 promoter methylation and 
endogenous WNK2 protein expression [16]. Cells were 
cultured in serum-free medium for 24 hours, then RNA 
was isolated and MMP2 and MMP9 mRNA levels were 
analyzed by quantitative Real-time PCR (qRT-PCR). As 
shown in Figure 1C, A172 cells express significantly 
higher levels of both MMP2 and MMP9 mRNA 
compared to SW1088 cells, (p < 0.001), suggesting 
that WNK2 is involved in the regulation of MMPs 
transcription.
WNK2 downregulation leads to an increase in 
MMP2 RNA levels and activity
To define the contribution of WNK2 to MMP2 
and MMP9 mRNA levels and activity, previously 
generated stable cell lines [16] were used, namely 
SW1088 cell line transfected either with a control 
shRNA (SW1088 C-) or a shRNA directed to WNK2 
(SW1088 shW2), and the A172 cell line transfected 
either with an empty vector (A172.Ev) or with 
a WNK2 expression vector (A172.W2). The levels of 
WNK2 expression were confirmed by semiquantitative 
RT-PCR as shown in Figure 2A. The analysis of 
MMP2 and MMP9 levels by qRT-PCR revealed that 
the silencing of WNK2 expression results in increased 
mRNA levels of the analyzed MMPs (Figure 2B). In 
contrast, ectopic expression of WNK2 caused markedly 
MMPs’ levels decrease (Figure 2B). To confirm if the 
differences at mRNA levels are also translated into 
different proteolytic activities, the conditioned media of 
the four cell lines, cultured for 24 hours in serum-free 
medium, were analyzed by gelatin zymography. It was 
found that the absence of WNK2 resulted in increased 
levels of both the inactive and active form of MMP2, 
whereas we were no able to find differences regarding 
MMP9 (Figure 2C). Overall, these results point to an 
important role of WNK2 as a negative modulator of 
MMP2 expression and activity.
WNK2 downregulation is associated with 
increased SRC and JNK activation levels
To elucidate the signaling mechanisms involved 
in MMP2 upregulation following WNK2 abrogation, 
we next examined the effect of WNK2 expression in 
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the activation of ERK, JNK, p38, and SRC, pivotal 
molecules in signaling pathways involved in different 
MMPs positive regulation, as well as in gliomas’ signaling 
mechanisms [22–29]. For this purpose SW1088 C-, 
SW1088 shW2, A172.Ev, and A172.W2 cell lines were 
left three hours in serum-free medium, then total lysates 
were prepared and the levels of activated phosphorylated 
ERK, JNK, p38, and SRC analyzed by Western Blot using 
specific antibodies. WNK2 downregulation in SW1088 
cells led to increased levels of JNK and SRC activation, 
and the opposite is observed when WNK2 is re-expressed 
in the A172 cell line with no endogenous WNK2 
expression (Figure 3B and 3D). In contrast, WNK2 was 
not associated with ERK and p38 activation in SW1088 
cells, although some decrease in the activation levels of 
ERK and p38 was observed after WNK2 overexpression 
in A172 cells (Figure 3A and 3C). Given these results, 
our further studies focused on JNK and SRC modulation 
by WNK2.
WNK2 modulates MMP2 expression by negative 
regulation of JNK
To confirm JNK and SRC as mediators of WNK2 
modulation of MMP2, their kinase activity was inhibited 
and the expression and activity levels of MMP2 were 
assessed in cells with and without WNK2. For this 
purpose, parental A172 cells were treated with chemical 
inhibitors of JNK (SP600125) and SRC (Saracatinib), 
or with the vehicle (DMSO) alone, at different 
concentrations, to choose the optimal concentration at 
which JNK and SRC were inactivated without affecting 
cell viability (Figure 4A). The viability of cells treated with 
the chosen concentration of each inhibitor was measured 
by MTS assay, and showed no significant difference when 
compared with treatment with DMSO alone (data not 
shown). The minimal effective concentration was then also 
confirmed in SW1088 shW2 cells. In order to determine 
the inhibitor effects on MMP2 expression by qRT-PCR, 
Figure 1: WNK2 protein expression associates with reduced MMP2 expression and activity. (A) MSP analysis of the WNK2 
gene promoter in a panel of glioma cell lines. (B) The activity of MMP2 and MMP9 was analyzed by gelatin zymography using conditioned 
medium of glioma cell lines with and without WNK2 expression. C+, positive control for MMP2 and MMP9, conditioned medium of a 
gastric cell line stimulated with macrophages. (C) MMP2 and MMP9 mRNA levels were measured by qRT-PCR in A172 and SW1088 cell 
lines. Relative expression changes in SW1088 are presented as fold increase of MMP/GAPDH in comparison to A172 cells. Data on graphs 
represent the mean values ± standard errors and are representative of, at least, three independent experiments. ***, significantly different 
from A172 cells (p < 0,001).
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and MMP2 activity by gelatin zymography, SW1088 sh C-, 
SW1088 shW2, and A172 were treated with JNK and 
SRC inhibitors or DMSO, for 24 hours, then conditioned 
media were used for zymography, and the cells for RNA 
extraction. The results showed that in SW1088 C- cells 
the treatment with JNK and SRC chemical inhibitors 
did not alter the levels of MMP2 expression, while in 
WNK2-silenced SW1088 cells the JNK inhibition resulted 
in reduced MMP2 mRNA, to levels comparable with 
control SW1088 cells transfected with a non-silencing 
shRNA (Figure 4B). The same reduction in MMP2 levels 
after JNK inhibition was also observed in parental A172, 
with no endogenous WNK2 expression (Figures 4B). In 
both cells lines with no WNK2 expression, this MMP2 
reduction also resulted in the decrease of secreted MMP2 
levels (Figure 4C). In contrast, the inhibition of SRC 
resulted in slightly enhanced expression of MMP2 in 
SW1088 shW2, and in a decrease of MMP2 expression 
in A172 cells, suggesting that the MMP2 regulation by 
WNK2 is not SRC dependent, but the SRC-dependent 
MMP2 expression modulation is potentially dependent 
of other factors specific of each cell line, independent of 
WNK2 expression status (Figure 4B). In both cells lines 
with no WNK2 expression the differences observed in 
MMP2 expression after SRC inhibition are paralleled 
by the correspondent alteration in MMP2 secretion 
(Figure 4C). Taken together, these results suggest that 
MMP2 expression and activity modulation by WNK2 is 
partially mediated by JNK.
MMP2 is involved in glioma cell invasion due to 
WNK2 downregulation
One of the main MMP2 functions is ECM 
remodeling leading to cell invasion, namely in gliomas 
[6, 30], and since our group has previously demonstrated 
that WNK2 is a negative regulator of glioma cell invasion 
[16], it was further determined whether MMP2 is involved 
in invasion of WNK2-negative cells. For this purpose, 
A172 cells were first treated for 24 hours with different 
concentrations of a chemical inhibitor of MMP2 activity 
(ARP 100) or with the vehicle (DMSO) alone, and the 
conditioned medium collected to perform zymography. 
Using this strategy, the optimal concentration at which 
MMP2 activity was inactivated was chosen (Figure 5A). 
Next, A172, A172.Ev, A172.W2, SW1088 C-, and SW1088 
shW2 were treated during the invasion assays either with 
MMP2 inhibitor or with DMSO alone for 24 hours. The 
inhibitor has no effect in the number of SW1088 C- 
invasive cells. SW1088 shW2 cells presented, as expected, 
increased number of invasive cells compared with 
SW1088 control cells. Interestingly, the treatment with 
the MMP2 inhibitor suppressed the invasion induced by 
the WNK2 silencing, suggesting the existence of a WNK2-
dependent MMP2 activity, which is involved in the glioma 
invasion (Figure 5B). In the same argument, in A172 cells, 
with no WNK2 expression, the MMP2 inhibition was also 
sufficient to significantly reduce the levels of invading 
cells (Figure 5C), and the same occurred in A172 cells 
Figure 2: WNK2 downregulation leads to an increase in MMP2 RNA levels and activity. (A) The expression of WNK2 was 
analyzed by RT-PCR, using specific primers, and β-actin was used as endogenous control. (B) MMP2 and MMP9 expression was analyzed 
by qRT-PCR. MMPs expression levels were normalized to GAPDH expression and results are presented as fold differences relative to 
SW1088 C- or A172.Ev cells. Data correspond to the mean values ± standard errors and are representative of, at least, three independent 
experiments. **, significantly different from SW1088 C- or A172.Ev cells (p < 0.01), ***, significantly different from A172.Ev cells 
(p < 0.001). (C) Conditioned medium of indicated cells were run on a gelatin zymogram to detect MMP activity. Proteolytic bands were 
revealed in white on a Coomassie Blue-stained background.
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transfected with an empty vector (Figure 5D). A172 cells 
stably expressing a WNK2 vector presented low levels of 
invasive cells when compared with A172 cells transfected 
with an empty vector, but in these cells the treatment 
with the MMP2 inhibitor do not significantly change the 
number of invasive cells when compared with A172.Ev 
cells treated only with the MMP2 inhibitor (Figure 5D). 
These findings demonstrate that WNK2 downregulation 
stimulate the invasive activity of glioma cells through 
the action of MMP2, and that MMP2 inhibition, in cells 
with WNK2, will no further enhance the decrease in the 
invasion levels, suggesting therefore therapeutic relevance.
WNK2 negatively regulates IL-6 expression
Gliomas contain high levels of inflammatory 
cytokines, namely IL-1β, IL-6, and IL-8, which are 
associated with increase invasion levels [31–33]. Once 
MMP2 is a regulator of interleukins [6], namely IL-6 
[34], and given our previously presented results, we 
interrogated whether WNK2 modulates IL-6 expression. 
For that purpose it was used the cell lines SW1088 C-, 
SW1088 shW2, A172.Ev, and A172.W2. The analysis 
of IL-6 levels by qRT-PCR revealed that the silencing of 
WNK2 expression results in increased mRNA levels of 
Figure 3: WNK2 downregulation is associated with increased SRC and JNK activation levels. Cell lysates were analyzed 
by Western Blot, immunostained with (A) an anti-phospho Thr202/Tyr204 ERK antibody, and re-stained after stripping of the same 
membrane for total ERK, and α-tubulin (B) an anti-phospho Thr183/Tyr185 JNK antibody, and re-stained for total JNK, and α-tubulin, after 
stripping, (C) an anti-phospho Thr180/Tyr182 p38 antibody, and re-stained for total p38, and α-tubulin after stripping of the membrane, 
(D)  an anti-phospho Tyr 416-SRC antibody, and re-stained for total SRC, and α-tubulin after stripping. Graphs correspond to the mean 
values ± standard errors and are representative of, at least, three independent experiments. *, significantly different from SW1088 C- or 
A172.Ev cells (p < 0.05), **, significantly different from SW1088 C- or A172.Ev cells (p < 0.01), ***, significantly different from A172.
Ev cells (p < 0.001).
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IL-6 (Figure 6A), and WNK2 re-expression in A172 cells 
resulted in IL-6 levels decrease (Figure 6A). To further 
assess if WNK2-dependent IL-6 modulation occurs in a 
JNK-dependent manner, SW1088 C-, SW1088 shW2, 
and A172 cells were treated either with JNK inhibitor 
(SP600125) or DMSO alone for 24 hours, and the cells 
used for RNA extraction, and qRT-PCR analysis. The 
results showed that when JNK activity was inhibited 
in cells with no WNK2 expression, the levels of IL-6 
decreased compared with cells treated with DMSO alone 
(Figure 6B). Taken together, these results showed that 
WNK2 depletion results in increased mRNA levels of 
IL-6, through a JNK-dependent mechanism.
To further confirm if these results are translated 
into different IL-6 secretion levels, the conditioned 
medium of SW1088 C-, SW1088 shW2, and A172, 
treated or not with the JNK inhibitor for 24 hours in 
serum-free medium, were analyzed by ELISA. Results 
confirmed that cells without WNK2 expression presented 
higher levels of secreted IL-6, as already observed at the 
mRNA level (Figure 6C). Regarding JNK modulation of 
IL-6 secretion, we found that in SW1088 C- and SW1088 
Figure 4: WNK2 modulates MMP2 expression by negative regulation of JNK. (A) A172 and SW1088 shW2 cells were 
treated for 3 hours with dimethyl sulfoxide vehicle (DMSO) (0), with a chemical inhibitor of JNK (SP600125; iJNK), or a chemical 
inhibitor of SRC (Saracatinib; iSRC). After treatment the cell lysates were analyzed by Western Blot, immunostained with anti-phospho 
Thr183/Tyr185 JNK or anti-phospho Tyr 416-SRC antibodies, and after stripping, the same membrane was immunostained for total JNK, 
and total SRC respectively. (B) The cells were treated for 24 hours with DMSO or the chemicals inhibitors of JNK (SP600125; iJNK) and 
SRC (Saracatinib; iSRC). MMP2 mRNA levels were measured by qRT-PCR. Relative expression changes are presented as fold increase 
of MMP2/GAPDH in comparison with A172 or SW1088 shW2 treated with DMSO. Data on graphs represent the mean values ±. standard 
errors and are representative of, at least, three independent experiments. *, significantly different from A172 or SW1088 shW2 cells 
treated with DMSO (p < 0.05), **, significantly different from A172 cells treated with DMSO (p < 0.01), ***, significantly different from 
SW1088 shW2 cells treated with DMSO (p < 0.001). (C) The cells were treated for 24 hours with DMSO or the chemicals inhibitors of 
JNK (SP600125; iJNK) and SRC (Saracatinib; iSRC). After the treatment the conditioned medium was collected and analyzed by gelatin 
zymograms to detect MMP activity. Proteolytic bands were revealed in white on a Coomassie Blue-stained background.
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shW2 cells the JNK inhibition resulted in a decrease in 
the IL-6 secreted levels, although in a non-significant 
manner (Figure 6C). In contrast, the JNK inhibition in 
A172 cells resulted in increased secreted IL-6 levels, 
leading us to suggest that IL-6 increased mRNA 
expression after WNK2 downregulation is mediated by 
JNK kinase, although this kinase is not involved in the 
processes associated with IL-6 secretion (Figure 6C). 
Since it is known that Rac1 is activated when WNK2 is 
downregulated [16], and it is described that a Rac/JNK 
signaling pathway stimulates IL-6 production [35], we 
tested whether in our model Rac1 is signaling upstream 
JNK in cells without WNK2 expression. For that purpose, 
SW1088 C-, SW1088 shW2, A172.Ev, and A172.
W2 cells were treated with a Rac1 chemical inhibitor 
(NSC23766), as previous described [36], and the levels 
of JNK activation were analyzed by western blot. We 
found that in every cell line the Rac1 inhibition resulted 
in higher levels of activated JNK comparing with non-
treated cells (Figure 6D), indicating that Rac1 is not 
signaling through JNK.
In silico validation of inverse correlation of 
WNK2 with MMP2, MMP9, and IL6 in gliomas
Since we found that the WNK2 expression status is 
associated with MMP2, MMP9 and IL6 expression (both 
mRNA and protein levels, Figures 2 and 6), we further 
validated and extended our results in human samples using 
an in silico approach. Using the TCGA database (http://
www.tcga-data.nci.nih.dov), the expression of WNK2, 
MMP2, MMP9 and IL6 genes was evaluated in a cohort 
of 275 glioma patients. Since the number of GBMs with 
high WNK2 expression is very limited (only 4 of 248 cases 
with log2 median-intensity value > 0), we grouped high 
and low-grade gliomas in order to assess the correlation of 
WNK2 levels with MMPs and IL6 expression. We found a 
strong inverse correlation between WNK2 expression and 
MMP2 (p < 0.001; Pearson R = -0.446) (Figure 7A) and 
MMP9 (p < 0.001; Pearson R = -0.472) levels (Figure 7B), 
and a low/moderated inverse correlation with IL6 
expression (p < 0.015; Pearson R = -0.146) (Figure 7C). 
These results corroborate our in vitro findings showing 
that WNK2 is a new negative regulator of MMP2, MMP9 
and IL6 expression in gliomas.
DISCUSSION
Invasion, a hallmark of cancer, is a complex process 
that involves several cellular modifications such as 
alterations in cell-cell and cell-matrix adhesion, acquisition 
of migration capacity and induction of proteolytic activity. 
The understanding of the molecular mechanisms that 
govern these cellular alterations is of crucial importance 
in the attempt of finding effective treatments of cancer. 
In the case of gliomas, the understanding of the invasive 
Figure 5: MMP2 is involved in glioma cell invasion due to WNK2 downregulation. (A) The activity of MMP-2 was analyzed 
by gelatin zymography using conditioned medium of A172 cells treated for 24 hours with dimethyl sulfoxide vehicle (DMSO) (0), or 
with a chemical inhibitor of MMP2 activity (ARP-100; iMMP2) at different concentrations. C+, positive control for MMP2 and MMP9, 
conditioned medium of a gastric cell line stimulated with macrophages. (B, C, D) Cells treated with DMSO or with ARP-100 were cultured 
for 24 hours on Matrigel coated filters. Data on graphs represent the mean values ± standard errors and are representative of, at least, three 
independent experiments. *, significantly different from A172 treated with DMSO (p < 0.05), **, significantly different from A172.Ev 
cells treated with DMSO (p < 0.01), ***, significantly different from SW 1088 C- or SW1088 shW2 cells treated with DMSO (p < 0.001).
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Figure 6: WNK2 negatively regulates IL-6 expression. (A) IL-6 expression was analyzed by qRT-PCR. IL-6 expression levels were 
normalized to GAPDH expression and results are presented as fold differences relative to SW1088 C- or A172.Ev cells. Data correspond 
to the mean values ± standard errors and are representative of, at least, three independent experiments. ***, significantly different from 
SW1088 C- or A172.Ev cells (p < 0.001). (B) The cells were treated for 24 hours with DMSO or the chemical inhibitor of JNK (SP600125; 
iJNK). IL-6 mRNA levels were measured by Real-time PCR. Relative expression changes are presented as fold increase of IL-6/GAPDH 
in comparison with A172 or SW1088 shW2 treated with DMSO. Data on graphs represent the mean values ±. standard errors and are 
representative of, at least, three independent experiments. **, significantly different from SW1088 shW2 treated with DMSO (p < 0.01), ***, 
significantly different from SW1088 C-or A172 cells treated with DMSO (p < 0.001). (C) The cells were treated for 24 hours with DMSO 
or the chemical inhibitors of JNK (SP600125; iJNK). After the treatment the conditioned medium was collected and analyzed using an IL-6 
ELISA assay. IL-6 levels are expressed as fold-increase over the levels in control conditions. Data on graphs represent the mean values ±. 
standard errors and are representative of, at least, three independent experiments. *, significantly different from A172 cells treated with 
DMSO (p < 0.05), ***, significantly different from SW1088 shW2 cells treated with DMSO (p < 0.001). (D) Cells were treated for 3 hours 
with H2O (-), or with a chemical inhibitor of Rac1 (NSC23766; iRac) (+). After treatment the cell lysates were analyzed by Western Blot, 
immunostained with anti-phospho Thr183/Tyr185 JNK antibody, and after stripping, the same membrane was immunostained for total JNK, 
and α-tubulin. Graphs correspond to the mean values ± standard errors and are representative of, at least, three independent experiments. 
*, significantly different from SW1088 C- cells (p < 0.05), **, significantly different from SW1088 C- or A172.Ev cells (p < 0.01).
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mechanisms gains an extra importance due to their highly 
invasion capacity, that impairs their complete resection 
during surgery, significantly reducing the effectiveness 
of current treatments, and increasing the chances of 
recurrence [2].
In a previous work, we showed that WNK2 was 
implicated as a negative regulator of invasion [16]. 
WNK2 downregulation was associated with an increase 
in Rac1 activity, a regulator of actin polymerization, 
which is involved in the establishment of lamellipodia and 
membrane ruffles, necessary for cell migration [37, 38]. 
The understanding of the cellular alterations associated 
with WNK2 downregulation are of great importance given 
the fact that a high percentage of gliomas present WNK2 
promoter methylation, compared with normal brain tissue 
[15, 16].
With this work, it was aimed to study whether 
WNK2 downregulation is associated with increased 
proteolysis mediated by MMPs, given their central role 
in extracellular matrix degradation, and consequently, 
invasion. Our data indicate for the first time that WNK2 
downregulation is associated with increased mRNA levels 
of MMP2 and MMP9, and increased activity levels of 
MMP2. These data have high relevance since the role 
of MMP2 in glioma pathogenesis and the association 
between MMP2 expression, cell invasion and disease 
severity is well-known [20, 21, 29, 39, 40]. The fact that 
the upregulation of MMP9 after WNK2 silencing is not 
associated with increased activity, may suggest that the 
post-translational activators of MMP2 and MMP9 are 
different and the activators of MMP9 are not affected 
by WNK2. By other hand, could be the case that MMP9 
alterations occur later in time, once MMP2 is a regulator 
of other MMPs and have a different activation kinetic.
Having established that WNK2 depletion is 
associated with an increase in the MMP2 expression 
and activity levels, and in the attempt to elucidate the 
intracellular signaling pathways that are involved in this 
process, we found that WNK2 negatively regulates JNK 
and SRC activation, and have no effect neither on ERK 
nor on p38 activation. It is of note that in case of JNK 
and ERK, our findings are not concordant with those 
previously reported in HeLa cervical cancer cells, a 
phenomena that may be associated with tissue specificities 
[13]. Interestingly, it was previously reported in gliomas 
that JNK may function as a positive regulator of MMP2 
activity, not by interfering with the MMP expression but 
by the regulation of TIMP2 expression, an activator of the 
pro-MMP2 [41]. This study was performed in a rat glioma 
cell line in which the WNK2 methylation status was not 
tested, and it cannot be excluded that the downregulation 
of WNK2 may activate alternative signaling pathways 
involving JNK kinase. Regarding SRC, to the best of our 
knowledge, it was the first time that a relation between 
this kinase and WNK2 status was analyzed. Despite the 
fact that we cannot conclude any association between 
the levels of SRC activation and MMP2 expression and 
activity, it is unquestionable that WNK2 modulates SRC 
activation. This finding is of particular interest because of 
SRC’s role in in vivo tumor growth and the promotion of 
glioma infiltration [42, 43]. The fact that SRC is associated 
with MMP2 regulation only in A172, and not in SW1088, 
could be occurring due to cell specific mutations in other 
genes, not related with WNK2 that can differently regulate 
SRC-dependent signaling pathways.
MMPs are involved in the regulation of several 
cellular processes beyond the ECM degradation, such as 
modification of cell surface receptors, release of growth 
factors, and regulation of inflammation and immunity 
cytokines, cell-cell adhesion molecules, and other 
proteinases [6–8]. To assess whether the alterations in 
MMP2 related to the WNK2 status were involved in the 
invasive process, glioma cells with or without WNK2 were 
treated with a chemical inhibitor of MMP2 activity. The 
results obtained after performing matrigel invasion assays 
indicate that MMP2 is necessary for glioma cell invasion, 
and that the WNK2 presence is sufficient to suppress the 
invasive phenotype. In cases where cells present WNK2 
Figure 7: In silico validation of inverse correlation of WNK2 with MMP2, MMP9, and IL-6 in gliomas. Microarray 
expression profiles of WNK2, MMP2, MMP9 and IL6 for glioma patients. In silico analysis indicates an inverse correlation between WNK2 
expression and MMP2 (A) MMP9 (B) and IL-6 (C) expression in glioma patients. Black squares indicate high-grade gliomas, and grey 
triangles low-grade gliomas.
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expression further inhibition of MMP2 activity have not 
any additional benefit to the invasion impairment. Judging 
from these results, we can suggest that the reduction of 
MMP2 expression levels, mediated by JNK inhibition, is 
sufficient and strong enough to alter the invasive behavior 
of the cell, impairing the infiltration of glioma.
Previous studies have shown the importance of IL-6 
chemokine in the invasive behavior of gliomas [31, 32] 
and its association with MMP2 [33, 34]. Additionally, Rac/
JNK signaling pathway was described to stimulate IL-6 
production in mast cells [35]. Therefore, we decided to 
address the issue of IL-6 regulation mediated by WNK2. 
We reported for the first time that WNK2 negatively 
regulates IL-6 mRNA expression, through JNK activity 
inhibition, once again pointing to the advantage of JNK 
inhibition in the disease context. These correlations were 
further corroborated by in silico analysis gathered by the 
TCGA dataset consisting of 275 gliomas patient.
Our group previously showed that Rac1 is 
upregulated following WNK2 silencing in gliomas [16]. 
Moreover, Rac1 is a known upstream regulator of JNK 
activity [44, 45], and both Rac1 and JNK are reported to 
be involved in MMP2 upregulation [46, 47]. Thus, we 
decided to evaluate whether Rac1 is signaling through 
JNK when WNK2 is downregulated. Our results showed 
that the Rac1 inhibition did not result in decrease JNK 
activation levels - as it was expected if Rac1 was signaling 
through JNK - but instead, we observed an increase in the 
JNK activation levels, eventually indicating a potential 
compensation mechanism, a frequent event in other 
signaling pathways [48].
Additionally, the present study can have potential 
therapeutic impact. It is known that MMP inhibitors are 
ineffective as therapeutic agents [49], therefore, targeting 
of molecules that function upstream the MMP expression 
and activation, would be of great value. In this line, our 
results point to the fact that either WNK2 re-expression 
or JNK inhibition may improve therapeutic modalities in 
the treatment of gliomas. Importantly, it has been reported 
that JNK inhibition enhances temozolomide cytotoxicity 
in human gliomas [50]. If we assume that JNK is a 
general MMP2 inhibitor in gliomas, even patients with 
normal WNK2 expression treated with a JNK inhibitor 
would better benefit from the treatment, both because 
of the invasion inhibition, and by the enhancement of 
temozolomide cytotoxicity.
In conclusion, the results reported in this study 
indicate, for the first time, that WNK2 silencing results 
in JNK activation, which in turn positively regulates IL-6 
and MMP2 expression and MMP2 activity, leading to 
increased levels of cell invasion. These in vitro findings 
may contribute to our understanding of the mechanisms 
that lead to glioma cell invasion in cases where WNK2 
is silenced by promoter hypermethylation, and provide a 
novel therapeutic strategy in glioma treatment.
MATERIALS AND METHODS
Cell culture and reagents
The adult glioma cell lines A172, U87-MG, 
SW1088, and SW1783, (ATCC; Manassas,VA, USA), 
SNB19, and GAMG (DSMZ; Braunschweig, Germany), 
U251, and U373 (kindly provided by Costello Laboratory 
[51]) were maintained in DMEM (Gibco; Grand Island, 
NY, USA) with 10% fetal bovine serum (FBS) (Gibco), 
200 μg/ml streptomycin, and 200 IU/ml penicillin (Gibco) 
at 37°C, under a humidified atmosphere containing 5% 
CO2. A172.Ev, A172.W2, SW1088 C-, and SW1088 
shW2 were generated and maintained as previously 
described [16].
Methylation specific PCR
Genomic DNA from glioma cell lines was isolated 
using TRIzol® Reagent (Invitrogen; Barcelona, Spain). 
300 ng of DNA were bisulphite treated using EZ DNA 
Methylation-GoldTM kit (Zymo Research Corporation, 
Irvine, CA, USA), and PCR performed using the specific 
primers described before [16]. Cp GenomeTM Universal 
Methylated DNA (Millipore; Billerica, MA, USA) was 
used as methylated control and blood DNA of a young 
healthy individual was used as unmethylated control.
Preparation of cell lysates
Cells were lysed in RIPA lysis buffer (50 mM 
Tris-HCl, 1% NP-40, 150 mM NaCl, 2 mM EDTA, 
pH 7.5) with protease inhibitors (Complete Mini protease 
inhibitor cocktail tablets, Roche; Mannheim, Germany) 
and phosphatase inhibitors (1 mM sodium vanadate, 
0.1 mM NaF, 2.5 mg/mL sodium pyrophosphate). 25 μg 
of protein were used for total lysates analysis. Proteins 
were separated by SDS-PAGE.
Immunoblot analysis
Proteins were transferred onto Hybond 
nitrocellulose membranes (GE Healthcare; Little Chalfont, 
Buckinghamshire, UK), blocked with 5% non-fat milk in 
PBS +0.1% Twen-20 (PBS-T) and incubated overnight 
at 4°C with primary antibody. The following antibodies 
were used: anti-phospho ERK (P-p44/42 MAPK T202/
Y204), anti-phospho JNK (P-SAPK/JNK T183/Y185), 
anti-phospho p38 (T180/Y182), anti-phospho SRC 
(Y416), anti-ERK, anti-JNK, anti-p38, anti-SRC (all 
from Cell Signaling Technology; Danvers, MA, USA), 
and anti-α-tubulin (Sigma-Aldrich; Madrid, Spain). HRP-
conjugated goat anti-mouse and goat anti-rabbit (Santa 
Cruz Biotechnology; Santa Cruz, CA, USA) were used 
as secondary antibodies. Subsequently ECL detection 
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(SuperSignal® West Femto, Thermo Scientific; Waltham, 
MA, USA) was performed. Band intensity was quantified 
using Image J software.
Preparation of conditioned medium
Conditioned medium was collected after cell 
maintenance in a serum-free medium for 24 hours, 
centrifuged at 13000 rpm for 5 min and filtered through 
0.2 μm pore size filters (Sterile Acrodisc®, Pall Corporation; 
Port Washington, NY, USA). To assess MMPs activity, 
conditioned medium was concentrated with acetone.
Zymography
MMP2 and MMP9 activity was assessed using 
concentrated protein from the conditioned medium. In 
each condition 5 μg of protein were loaded on a 10% 
SDS-PAGE, containing 1 mg/mL gelatin as substrate. 
Zymograms were run in a Tris/glycine SDS running buffer 
under nondenaturing conditions. After electrophoresis, 
gels were washed twice with 2% Triton X-100, to remove 
SDS remnants. Zymograms were subsequently incubated 
for 16 hours at 37°C in a MMP substrate buffer (50 mM 
Tris-HCl, 10 mM CaCl2, pH 7.5). Proteolytic activity was 
visualized as the presence of clear bands against a blue 
background after Coomassie Blue gel staining.
Quantification of mRNA by quantitative Real-
Time PCR and semiquantitative RT-PCR
Total RNA was extracted using TRIzol® 
Reagent (Invitrogen). One μg of RNA was used for 
cDNA synthesis, using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems; 
Branchburg, NJ, USA). Semiquantitative RT-PCR 
to WNK2 was performed using the primers Fw 
(5′-GTGCACGATCCTGAAATCAA-3′) and Rv (5′- 
CAGTTTCTTGGGGTCTTCCA-3′) (exon 6), and β-actin 
was used as housekeeping gene with the primers Fw 
(5′- GGACTTCGAGCAAGAGATGG-3′) (exon 3), and 
Rv (5′- AGCACTGTGTTGGCGTACAG-3′) (exon 4), 
and Platinum® Taq DNA Polymerase (Invitrogen). Real-
time PCR to MMPs was performed using TaqMan Mix 
(Applied Biosystems) and the MMP2 (Hs01548727_m1) 
and MMP9 TaqMan probes (Hs00234579_m1) (Applied 
Biosystems). Relative MMP expression was normalized to 
levels of GAPDH (Human GAPDH Endogenous Control 
(FAM™ Dye/MGB Probe, Non-Primer Limited), (Applied 
Biosystems). PCR was performed in a 7500 Real Time 
PCR System (Applied Biosystems).
Real-time PCR to IL-6 was performed 
using the SsoFastTM EvaGreen® Supermix 
(BioRad; Hercules, CA, USA), according to the 
manufactures’ instructions, using the IL-6 primers Fw 
(5′-AAAGAGGCACTGGCAGAAAA-3′) and Rv 
(5′- CAGGGGTGGTTATTGCATCT-3′) (exon 2), and 
β-actin was used as housekeeping gene with the primers 
Fw (5′- GGACTTCGAGCAAGAGATGG-3′) (exon 3), 
and Rv (5′- AGCACTGTGTTGGCGTACAG-3′) (exon 4). 
Relative IL-6 expression was normalized to levels of 
β-actin. PCR was performed in a Bio-Rad CFX96TM Real 
Time PCR System (Bio-Rad).
Cell treatment
Pharmacological inhibitors SP600125 and ARP 
100 were obtained from Cayman Chemicals (Ann Arbor, 
MI, USA), Saracatinib from Selleckchem (Houston, TX, 
USA), and NSC23766 from Calbiochem (San Diego, CA, 
USA). The concentrations of inhibitors used were 25 μM 
for SP600125, 5 μM for Saracatinib, and 100 μM for ARP 
100 and NSC23766. Cells were treated for 3 hours in 
serum-free medium for total cell lysates, or for 24 hours, 
for conditioned medium, RNA, and invasion assays.
Cell viability assay
Cells were plated in a 96-wells plate at a density of 
3 × 103 per well, and allowed to adhere overnight. Cells 
were treated with chemical inhibitors or with DMSO, as 
a negative control, in DMEM supplemented with 0.5% 
FBS for 24 hours. After this period, cell viability was 
quantified using CellTiter 96 Aqueous Cell Proliferation 
Assay (MTS) (Promega; Madison, WI, USA). The results 
were expressed as mean viable cells in relation to DMSO 
alone, considered as 100% viable.
Invasion assays
Matrigel-coated 24-well invasion inserts of 8 μm 
pore-size filters (BD Biosciences; Madrid, Spain) were 
incubated one hour at 37°C with antibiotic-free medium. 
After this period, 5 × 104 cells, in antibiotic-free medium, 
either with the MMP2 chemical inhibitor (ARP 100), or 
with DMSO, as negative control, were incubated on top 
of the filters for 24 hours at 37°C. Filters were washed 
with PBS and fixed in cold methanol. Invasive cells were 
stained and mounted in Vectashield with DAPI (Vector 
Laboratories; Burlingame, CA, USA), and visualized 
through an Olympus BX61 fluorescence microscope 
(Olympus, Hamburg, Germany). Invasive cells were 
scored in at least 20 microscopic fields (20X objective).
IL-6 ELISA assay
Conditioned media from cells was collected after 
24 hours treatment with the JNK inhibitor or DMSO in 
serum free medium. Quantification of secreted IL-6 was 
assessed by an IL-6 ELISA kit (LEGEND MAXTM Human 
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IL-6, Biolegend, San Diego, CA, USA), according to the 
manufacturer’s instructions. IL-6 levels were expressed as 
fold-increase over the levels in control conditions.
In silico, microarray expression analysis
Microarray expression data was downloaded for 
275 glioma patients (248 high grade and 27 low grade 
gliomas) with expression available for WNK2, MMP2, 
MMP9, and IL6 from The Cancer Genome Atlas (TCGA) 
database (http://www.tcga-data.nci.nih.dov).
Statistical analysis
Data were analyzed with Student’s t-test and 
expressed as mean values of at least three independent 
experiments ± standard errors. Pearson test was used to 
evaluate the correlation between gene expression profiles 
from TCGA database. Differences were considered 
significant at *p < 0.05, **p < 0.01, and ***p < 0.001.
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